Page 59 - NobleCon21

Can-Fite BioPharma Ltd.

SELECTED FINANCIAL ITEMS CANF
(in millions of USD)
CQ4 '24 CQ1 '25 CQ2 '25 CQ3 '25 LTM
Income Statement Key Items
Total Revenue 0.18 0.18 0.10 0.10 0.56
Gross Profit 0.18 0.18 0.10 0.10 0.56
Gross Margin 100% 100% 100% 100% 100%
EBIT (2.02) (2.02) (2.45) (2.45) (8.93)
EBIT Margin -1127% -1127% -2425% -2425% -1595%
Net Income to Common Shareholders (1.96) (1.96) (2.44) (2.44) (8.80)
Net Margin -1096% -1096% -2414% -2414% -1571%

Balance Sheet Key Items
Total Assets 9.12 9.12 7.72 7.72 7.72
Cash & Short Term Investments 4.83 4.83 6.45 6.45 6.45
% of Assets 53% 53% 84% 84% 84%
Current Assets -Total 8.98 8.98 7.62 7.62 7.62
% of Assets 98% 98% 99% 99% 99%
Total Liabilities 3.68 3.68 3.54 3.54 3.54
% of Assets 40% 40% 46% 46% 46%
Current Liabilities - Total 2.05 2.05 2.12 2.12 2.12
% of Assets 23% 23% 27% 27% 27%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 5.44 5.44 4.18 4.18 4.18
% of Assets 60% 60% 54% 54% 54%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (1.80) (1.80) (2.38) (2.38) (8.35)
Net Cash Flow - Investing (1.50) (1.50) 1.50 1.50 (0.00)
Net Cash Flow - Financing 3.36 3.36 1.69 1.69 10.08

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference